Foghorn Therapeutics Inc. (FHTX)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$90.9M
Cash & Equivalents
$25.3M
Quarterly Burn Rate
11 mo
Est. Cash Runway
$349M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (2)

NCT #TitlePhaseStatusEnrollment
NCT07283094 FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia PHASE1 Recruiting 33
NCT04891757 FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies PHASE1 Active Not Recruiting 144

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for FHTX.

SEC EDGAR Filings

All SEC filings for Foghorn Therapeutics Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.